期刊文献+

可溶性gp130酶联检测试剂盒的研制及其运用 被引量:8

Preparation of sgp130 ELISA kit and its application
下载PDF
导出
摘要 目的 :建立灵敏、特异、稳定和简便的人可溶性gp130 (sgp130 )酶标检测试剂盒。方法 :采用本室制备的鼠抗人gp130单抗T2作为包被单抗 ,另一株识别不同抗原位点的单抗T12经生物素 (biotin)标记后作为检测抗体 ,建立双单抗夹心的人sgp130酶标检测方法 ,并分别测定了 40例健康供血员、40例甲亢及 47例慢性肾炎患者血清中sgp130的含量。结果 :成功地研制了人sgp130酶联检测试剂盒 ,其灵敏度为 10ng/ml。该试剂盒 4℃放置 3个月 ,离散度 (CV) <± 7 6 %,回收率为95 %~ 111%,提示检测方法具有良好的灵敏度、稳定性和准确性。用该试剂盒测得的血清中sgp130含量的 95 %正常值范围为5 36 92~ 2 87 88(ng/ml) ,甲亢及慢性肾炎患者血清中sgp130的含量分别为 937 16± 2 17 5 9和 80 6 4 5± 138 4 7(ng/ml) ,明显高于正常对照者 (P <0 0 1)。结论 :建立的人sgp130酶标检测试剂盒 ,能够对血清中sgp130进行准确定量 ,可为临床gp130相关性疾病的辅助诊断、疗效估价和判断预后提供有价值的生物学参数 ,具有良好的运用前景。 Objective:To establish the sensitive,specific,stable and convenient sgp130 ELISA kit.Methods:The mAb T2 against human gp130 was used as coating antibody;the other mAb T12 recognized different epitope with T2 was labeled by biotin,then a ELISA kit for detecting sgp130 was set up.Results:sgp130 ELISA kit is successfully established and its sensitivity is 10 ng/ml.After the kit is placed in 4℃ for 3 months,the kit's CV is less than ±7.6% and the retrievable rate is 95%~111%.These indicate that it has highly sensitivity,stability and accuracy.The normal serum concentration of sgp130 in healthy donors is 536.92~287.88(ng/ml),but there is higher in patients with hyperthyroidism(937.16±217.5) and chronic nephritis(806.45±138.47).Significant difference is found comparing with normal control(P< 0.01). Conclusion:sgp130 ELISA kit may be of value in basic studies and contribute to gp130 related diseases' diagnosis,curative effects' evaluation and prognosis in clinic.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2002年第3期172-174,共3页 Chinese Journal of Immunology
基金 国家自然科学基金资助 ( 396 2 5 0 2 4)
  • 相关文献

参考文献3

二级参考文献3

共引文献28

同被引文献39

  • 1王海涛,贾建平.多发性硬化患者血清与脑脊液中白介素6及其可溶性受体成分sIL-6Rs、gp130的研究[J].中国神经免疫学和神经病学杂志,2005,12(5):247-249. 被引量:3
  • 2EIKEN H G, OIE E, DAMAS J K, et al. Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end stage human heart failure[J]. Eur J Clin Invest, 2001,31:389-397.
  • 3AUER J, BCRENT R, LASSNIG E, et al. C reactive protein and coronary arterydisease[J]. Jpn Heart J, 2002,43 (6) : 607-619.
  • 4FISCHER P, HILFIKER-KIEINER D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects[J]. British Journal of Pharmacology, 2008,153(6) :414-427.
  • 5RIDLER P M, HENEKERRS C H, BUHNG J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J].N Enlg L J Med, 2000,342(12):836-843.
  • 6EIKEN H G,OIE E,DAMAS J K,et al.Myocardial gene expression of leukaemia inhibitory factor,interleukin-6 and glycoprotein 130 in end-stage human heart failure[J].Eur J Clin Invest,2001,31:389-397.
  • 7FISCHER P,HILFIKER-KLEINER D.Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects[J].Bri J Pharm,2008,153(6):414-427.
  • 8WINGING S,KENER F,STEINBACH G,et al.Specificity of cardiac troponin T in renal disease[J].Clin Chem Lab Med,1998,36(2):87-92.
  • 9KAVSAK P A,MACRAE A R,LUSTIG V,et al.The impact of the ESC/ACCredefintion of myocardial infarctin and new sensitive troponin assay on the frequency of acute myocardial infarction[J].Am Heart J,2006,152:118-125.
  • 10Okopien B, BasiakM, M adejA, et al. Markers of inflammatory process in stable and unstable coronary arterydisease[J]. Pol Merkur Lekarsk,2006,21( 121 ) : 69-72.

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部